Lorenz  Muller net worth and biography

Lorenz Muller Biography and Net Worth

Chief Commercial Officer of Milestone Pharmaceuticals

Mr. Muller has served as Milestone’s Chief Commercial Officer since October 2017. Mr. Muller has almost 30 years of pharmaceutical industry experience where he served startup-to-large multinational companies. Prior to joining Milestone, he led the marketing team at Exact Sciences Corporation with accountability for developing and implementing all aspects of Exact Sciences’ marketing plans. Before that Mr. Muller led the thrombosis franchise at Daiichi Sankyo with US responsibility for the launch and Profit and Loss of cardiovascular blood-thinning drugs Effient® (prasugrel) and Savaysa® (edoxaban). Prior to Daiichi Sankyo, he was Vice President of Marketing and Healthcare Outcomes at CV Therapeutics, where he played a foundational role in the transition of the company from an R&D company to a commercial organization and oversaw the launch of Ranexa® (ranolazine), a first-in-class treatment for chronic angina.

Before joining CV Therapeutics, Mr. Muller held various positions in sales and marketing at Merck & Co., Inc., including product management as part of the hypertension and heart failure business group. He also served as a consultant for Arthur D. Little, Inc, for five years completing technology-based consulting assignments for a large number of biotechnology, pharmaceutical, and fine chemical clients.

Mr. Muller received a BS in both Chemical Engineering and Life Sciences and a MS in Chemical Engineering from the Massachusetts Institute of Technology. He earned his MBA from the Harvard Graduate School of Business Administration.

What is Lorenz Muller's net worth?

The estimated net worth of Lorenz Muller is at least $257.78 thousand as of January 26th, 2026. Mr. Muller owns 205,406 shares of Milestone Pharmaceuticals stock worth more than $257,785 as of August 10th. This net worth evaluation does not reflect any other assets that Mr. Muller may own. Learn More about Lorenz Muller's net worth.

How do I contact Lorenz Muller?

The corporate mailing address for Mr. Muller and other Milestone Pharmaceuticals executives is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. Milestone Pharmaceuticals can also be reached via phone at (514) 336-0444 and via email at [email protected]. Learn More on Lorenz Muller's contact information.

Has Lorenz Muller been buying or selling shares of Milestone Pharmaceuticals?

Lorenz Muller has not been actively trading shares of Milestone Pharmaceuticals during the past quarter. Most recently, Lorenz Muller sold 11,180 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a transaction totalling $21,577.40. Following the completion of the sale, the insider now directly owns 205,406 shares of the company's stock, valued at $396,433.58. Learn More on Lorenz Muller's trading history.

Who are Milestone Pharmaceuticals' active insiders?

Milestone Pharmaceuticals' insider roster includes David Bharucha (Chief Medical Officer), Lorenz Muller (Chief Commercial Officer), Jeffrey Nelson (Chief Operating Officer), and Joseph Oliveto (President and Chief Executive Officer). Learn More on Milestone Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Milestone Pharmaceuticals?

During the last twelve months, insiders at the sold shares 11 times. They sold a total of 452,827 shares worth more than $1,017,948.37. The most recent insider tranaction occured on April, 16th when CEO Joseph Oliveto sold 36,500 shares worth more than $82,490.00. Insiders at Milestone Pharmaceuticals own 5.0% of the company. Learn More about insider trades at Milestone Pharmaceuticals.

Information on this page was last updated on 4/16/2026.

Lorenz Muller Insider Trading History at Milestone Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/26/2026Sell11,180$1.93$21,577.40205,406View SEC Filing Icon  
12/15/2025Sell53,566$2.32$124,273.12196,486View SEC Filing Icon  
See Full Table

Lorenz Muller Buying and Selling Activity at Milestone Pharmaceuticals

This chart shows Lorenz Muller's buying and selling at Milestone Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Milestone Pharmaceuticals Company Overview

Milestone Pharmaceuticals logo
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Read More

Today's Range

Now: $1.27
Low: $1.20
High: $1.28

50 Day Range

MA: $1.24
Low: $1.04
High: $1.36

2 Week Range

Now: $1.27
Low: $1.00
High: $3.06

Volume

1,342,655 shs

Average Volume

1,872,258 shs

Market Capitalization

$157.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98